Anti-Tumoral Effects of Anti-Progestins in a Patient-Derived Breast Cancer Xenograft Model
- 410 Downloads
Breast cancer is a hormone-dependent disease in which estrogen signaling targeting drugs fail in about 10 % due to resistance. Strong evidences highlighted the mitogen role of progesterone, its ligands, and the corresponding progesterone receptor (PR) isoforms in mammary carcinoma. Several PR antagonists have been synthesized; however, some of them are non-selective and led to side or toxic effects. Herein, we evaluated the anti-tumor activity of a commercially available PR modulator, ulipristal acetate (UPA), and a new selective and passive PR antagonist “APR19” in a novel preclinical approach based on patient-derived breast tumor (HBCx-34) xenografted in nude mice. As opposed to P4 that slightly reduces tumor volume, UPA and APR19 treatment for 42 days led to a significant 30 % reduction in tumor weight, accompanied by a significant 40 % retardation in tumor growth upon UPA exposure while a 1.5-fold increase in necrotic areas was observed in APR19-treated tumors. Interestingly, PR expression was upregulated by a 2.5-fold factor in UPA-treated tumors while APR19 significantly reduced expression of both PR and estrogen receptor α, indicating a potential distinct molecular mechanism among PR antagonists. Cell proliferation was clearly reduced in UPA group compared to vehicle conditions, as revealed by the significant reduction in Ki-67, Cyclin D1, and proliferating cell nuclear antigen (PCNA) expression. Likewise, an increase in activated, cleaved poly(ADP-ribose) polymerase (PARP) expression was also demonstrated upon UPA exposure. Collectively, our findings provide direct in vivo evidence for anti-progestin-mediated control of human breast cancer growth, given their anti-proliferative and pro-apoptotic activities, supporting a potential role in breast cancer therapy.
KeywordsProgesterone Receptor Proliferate Cell Nuclear Antigen Progesterone Receptor Expression Proliferate Cell Nuclear Antigen Expression Ulipristal Acetate
- PR antagonists
This study was supported by fundings from Institut National de la Santé et de la Recherche Médicale (Inserm), Université Paris Sud, and a grant from La Ligue Nationale Contre le Cancer (to FJ and ML). The authors would like to thank Pr Jean-Daniel Brion, Dr Marie-Edith Rafestin-Oblin, and Dr Junaid Ali Khan for their help and comments during the initial phase of this work.
The funder HRA Pharma provided grant together with the national agency for Research (ANRT/HRA pharma CIFRE, i.e., Conventions Industrielles de Formation par la Recherche, in English Research Training Industrial Grant Contract) for [NE], support in the form of salary for one author [MRR], but did not have any additional role in the study design, data collection and analysis, or preparation of the manuscript.
Compliance with Ethical Standards
Conflict of Interest
MRR is an employee of HRA Pharma.
NE is a recipient of a joint ANRT/HRA Pharma grant.
NCB is a member of the European board of Gedeon Richter, without personal income.
- 2.Bakker GH, Setyono-Han B, Henkelman MS, de Jong FH, Lamberts SW, van der Schoot P, Klijn JG (1987) Comparison of the actions of the antiprogestin mifepristone (RU486), the progestin megestrol acetate, the LHRH analog buserelin, and ovariectomy in treatment of rat mammary tumors. Cancer Treatment Reports 71(11):1021–1027PubMedGoogle Scholar
- 8.Cottu P, Bieche I, Assayag F, El Botty R, Chateau-Joubert S, Thuleau A, Bagarre T et al (2014) Acquired resistance to endocrine treatments is associated with tumor-specific molecular changes in patient-derived luminal breast cancer xenografts. Clin Cancer Res 20(16):4314–4325. doi: 10.1158/1078-0432.ccr-13-3230 CrossRefPubMedGoogle Scholar
- 14.Esber N, Le Billan F, Resche-Rigon M, Loosfelt H, Lombes M, Chabbert-Buffet N (2015) Ulipristal acetate inhibits progesterone receptor isoform A-mediated human breast cancer proliferation and BCl2-L1 expression. PLoS One 10(10):e0140795. doi: 10.1371/journal.pone.0140795 CrossRefPubMedPubMedCentralGoogle Scholar
- 21.Huniadi CA, Pop OL, Antal TA, Stamatian F (2013) The effects of ulipristal on Bax/Bcl-2, cytochrome c, Ki-67 and cyclooxygenase-2 expression in a rat model with surgically induced endometriosis. Eur J Obstet Gynecol Reprod Biol 169(2):360–365. doi: 10.1016/j.ejogrb.2013.03.022 CrossRefPubMedGoogle Scholar
- 22.Kamangar F, Dores GM, Anderson WF (2006) Patterns of cancer incidence, mortality, and prevalence across five continents: defining priorities to reduce cancer disparities in different geographic regions of the world. J Clin Oncol 24(14):2137–2150. doi: 10.1200/jco.2005.05.2308 CrossRefPubMedGoogle Scholar
- 24.Khan JA, Bellance C, Guiochon-Mantel A, Lombes M, Loosfelt H (2012) Differential regulation of breast cancer-associated genes by progesterone receptor isoforms PRA and PRB in a new bi-inducible breast cancer cell line. PLoS One 7(9):e45993. doi: 10.1371/journal.pone.0045993 CrossRefPubMedPubMedCentralGoogle Scholar
- 29.Leonhardt SA, Edwards DP (2002) Mechanism of action of progesterone antagonists. Exp Biol Med (Maywood) 227(11):969–980Google Scholar
- 32.Liang Y, Hou M, Kallab AM, Barrett JT, El Etreby F, Schoenlein PV (2003) Induction of antiproliferation and apoptosis in estrogen receptor negative MDA-231 human breast cancer cells by mifepristone and 4-hydroxytamoxifen combination therapy: a role for TGFbeta1. Int J Oncol 23(2):369–380PubMedGoogle Scholar
- 41.Mote PA, Leary JA, Avery KA, Sandelin K, Chenevix-Trench G, Kirk JA, Clarke CL (2004) Germ-line mutations in BRCA1 or BRCA2 in the normal breast are associated with altered expression of estrogen-responsive proteins and the predominance of progesterone receptor A. Genes Chromosom Cancer 39(3):236–248CrossRefPubMedGoogle Scholar
- 54.Schreiber, V, Illuzzi G, Heberle E, Dantzer F. 2015. [From poly(ADP-ribose) discovery to PARP inhibitors in cancer therapy]. Bull Cancer. doi: 10.1016/j.bulcan.2015.07.012
- 55.Wargon V, Riggio M, Giulianelli S, Sequeira GR, Rojas P, May M, Polo ML et al (2015) Progestin and antiprogestin responsiveness in breast cancer is driven by the PRA/PRB ratio via AIB1 or SMRT recruitment to the CCND1 and MYC promoters. Int J Cancer 136(11):2680–2692. doi: 10.1002/ijc.29304 CrossRefPubMedGoogle Scholar
- 60.Xu Q, Takekida S, Ohara N, Chen W, Sitruk-Ware R, Johansson ED, Maruo T (2005) Progesterone receptor modulator CDB-2914 down-regulates proliferative cell nuclear antigen and Bcl-2 protein expression and up-regulates caspase-3 and poly(adenosine 5′-diphosphate-ribose) polymerase expression in cultured human uterine leiomyoma cells. J Clin Endocrinol Metab 90(2):953–961. doi: 10.1210/jc.2004-1569 CrossRefPubMedGoogle Scholar
- 61.Yun BS, Seong SJ, Cha DH, Kim JY, Kim ML, Shim JY, Park JE (2015) Changes in proliferating and apoptotic markers of leiomyoma following treatment with a selective progesterone receptor modulator or gonadotropin-releasing hormone agonist. Eur J Obstet Gynecol Reprod Biol 191:62–67. doi: 10.1016/j.ejogrb.2015.05.022 CrossRefPubMedGoogle Scholar